Navigation Links
Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
Date:8/19/2007

Estimates Peak Worldwide Transplant Opportunity of Over $400 Million

Annually

CAMBRIDGE, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) today announced that its second phase 3 trial of Mozobil(TM) (plerixafor) has successfully met its primary and secondary endpoints, demonstrating positive results in multiple myeloma (MM) similar to those reported two weeks ago in non-Hodgkin's lymphoma.

The combined strength of these two trials -- in which patients with two types of cancer achieved more rapid and effective mobilization of stem cells in preparation for transplant than patients treated with current therapies -- will support Mozobil's regulatory approval, commercialization, and likely adoption as a standard of care in transplantation.

The randomized, double-blind, placebo-controlled trial included 302 patients who were undergoing a hematopoietic stem cell transplant (HSCT) for multiple myeloma at medical centers in the United States, Canada, and Europe. Like the previous trial, it examined the effectiveness of Mozobil in increasing the number of hematopoietic stem cells collected for a transplant, comparing the stem cell yield from patients treated with Mozobil following G- CSF to patients treated with placebo following G-CSF.

In the primary efficacy endpoint, 72 percent of patients treated with Mozobil and G-CSF achieved the target threshold for collection of at least 6 million CD34+cells/kg from the peripheral blood with two days or fewer of apheresis sessions, compared with 34 percent of patients in the G-CSF/placebo group. This two-fold increase was statistically significant in favor of the Mozobil-treated patients (p<0.0001). Like th
'/>"/>

SOURCE Genzyme Corp.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Sygnis Pharma AG announces date for presentation of clinical results
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... DALLAS and NEW YORK ... (OTCBB: ACCP), a developer of new products for oncology ... mucositis, MuGard ® , has been featured in an ... Oral Mucositis Symptoms in Head and Neck Cancers."  Dr. ... mucositis, provides insight on the growing demand seen in ...
(Date:7/30/2014)... , July 30, 2014   Medical Equipment ... have been awarded a Department of Defense (US Army) ... to supply a mobile MRI diagnostic machine and technical ... Business (WOSB) through the Small Business Administration (SBA), Medical ... the field with the latest medical diagnostic equipment. The ...
(Date:7/30/2014)... SUNNYVALE, California , July 30, 2014 /PRNewswire/ ... GPU technology and CUDA programming expertise to big ... other markets  eInfochips, a leading engineering ... to clients to develop NVIDIA GPU-powered solutions for ... , high-performance computing (HPC), industrial ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... NATICK, Mass., May 6, 2011 Boston Scientific ... the launch and first implants of its ENERGEN™ ... implantable cardioverter defibrillators (ICDs) in Europe and other ... thinnest high-energy devices to treat heart failure and ...
... BD Diagnostics, a segment of BD (Becton, Dickinson and ... launch of the BD MAX™ Open System for molecular testing, ... developed assays and offer enhanced testing services that elevate the ... the launch announcement on the opening day of the 21st ...
Cached Medicine Technology:Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 2Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 3Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 4BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 2BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 3BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 4
(Date:7/31/2014)... The study, The Truth Behind Variation in ... care payments for four clinical areas—congestive heart failure, acute ... and knees). Using the definition of episodes of ... program, the study examines these clinical areas within the ... , “Our study reaffirms that, in most instances, the ...
(Date:7/30/2014)... Riverdale, NJ (PRWEB) July 31, 2014 ... in Macy’s ninth annual national “Shop For A Cause” ... For A Cause” is a unique one-day-only shopping event ... helped raise more than $44 million for charities across ... year’s event by purchasing shopping passes from Push to ...
(Date:7/30/2014)... Dayton, Ohio (PRWEB) July 31, 2014 ... welcome Douglas A. Fecher President and CEO, Wright-Patt Credit ... , Fecher, is a foremost financial CEO with an ... vice president of lending and later chief operating officer ... 2000, Fecher has led the Beavercreek-based Wright-Patt Credit Union ...
(Date:7/30/2014)... 31, 2014 WalkingSticksandCane.com has just ... The ladies will love the new European fashions and the ... These sticks and canes are from one from one of ... of the styles re unique and offer the consumer the ... Blackthorn Walking Sticks are some of the rarest and most ...
(Date:7/30/2014)... born with severe combined immunodeficiency (SCID) can be successfully ... to experts led by Memorial Sloan Kettering,s Richard J. ... transplant protocols. Their review will be published in the ... of Medicine . , SCID is a group of ... malfunction. When this breakdown occurs, babies no longer have ...
Breaking Medicine News(10 mins):Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:European Walking Sticks from WalkingSticksandCane.com 2Health News:Transplantation shown to be highly effective in treating immune deficiency in children 2
... Despite of the significant improvements in dialysis treatments, over ... U.S. Hemodialysis International, which published the// study, finds ... malnutrition. ,Large Body Mass Combats Effects ... what has been termed the “obesity paradox,” wherein obesity ...
... health crisis triggered by the death of over 40 ... institution's laboratory, has prompted Panamanian President// Martin Torrijos to ... ,Torrijos said that the government had since closed ... Body (CSS), permanently in a bid to win back ...
... a new study, septic shock—a dangerous, often deadly runaway ... research also suggests how a drug might// temper sepsis. ... been revealed in an experimental animal. ... Sabin Professor of Microbiology and Molecular Pathogenesis at NYU ...
... grow old in good health should have strong grip, not ... recent study.// ,A 40-year study of nearly 6000 ... nine factors that were good predictors of which middle-aged men ... ,The nine factors were: not being overweight, low blood sugar ...
... women who complain of severe itching and redness of skin ... intercourse that has been now confirmed by doctors as a ... present in semen. Thankfully doctors have given the hope to ... according to the report made in LiveScience. ,The ...
... More than 80,000 people in the United States are on ... for the death of a matching donor, but more and ... ,Last year nearly 7,000 people donated a kidney, segment of ... in need of a transplant. In fact at some major ...
Cached Medicine News:Health News:New Study Finds On/Off Switch for Septic Shock 2Health News:Keys to Good Health in Old Age Begins in Midlife 2Health News:See, men cause allergies in women after sex 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 3
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Permanent, sutureless, epicardial pacing leads...
Medicine Products: